Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

被引：21

作者：

Guan, Wei-jie ^{[1
,2
]}

Liang, Wen-hua ^{[2
,3
]}

Zhao, Yi ^{[2
,3
]}

Liang, Heng-rui ^{[2
,3
]}

Chen, Zi-sheng ^{[2
,3
,4
]}

Li, Yi-min ^{[2
,5
]}

Liu, Xiao-qing ^{[2
,5
]}

Chen, Ru-chong ^{[1
,2
]}

Tang, Chun-li ^{[1
,2
]}

Wang, Tao ^{[1
,2
]}

Ou, Chun-quan ^{[6
]}

Li, Li ^{[6
]}

Chen, Ping-yan ^{[6
]}

Sang, Ling ^{[2
,5
]}

Wang, Wei ^{[2
,3
]}

Li, Jian-fu ^{[2
,3
]}

Li, Cai-chen ^{[2
,3
]}

Ou, Li-min ^{[2
,3
]}

Cheng, Bo ^{[2
,3
]}

Xiong, Shan ^{[2
,3
]}

Ni, Zheng-yi ^{[7
]}

Xiang, Jie ^{[7
]}

Hu, Yu ^{[8
]}

Liu, Lei ^{[9
,10
]}

Shan, Hong ^{[11
]}

Lei, Chun-liang ^{[12
]}

Peng, Yi-xiang ^{[13
]}

Wei, Li ^{[14
]}

Liu, Yong ^{[15
]}

Hu, Ya-hua ^{[16
]}

Peng, Peng ^{[17
]}

Wang, Jian-ming ^{[18
]}

Liu, Ji-yang ^{[19
]}

Chen, Zhong ^{[20
]}

Li, Gang ^{[21
]}

Zheng, Zhi-jian ^{[22
]}

Qiu, Shao-qin ^{[23
]}

Luo, Jie ^{[24
]}

Ye, Chang-jiang ^{[25
]}

Zhu, Shao-yong ^{[26
]}

Cheng, Lin-ling ^{[1
,2
]}

Ye, Feng ^{[1
,2
]}

Li, Shi-yue ^{[1
,2
]}

Zheng, Jin-ping ^{[1
,2
]}

Zhang, Nuo-fu ^{[1
,2
]}

Zhong, Nan-shan ^{[1
,2
]}

He, Jian-xing ^{[2
,3
]}

机构：

[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Peoples R China

[2] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China

[3] Guangzhou Med Univ, China State Key Lab Resp Dis, Dept Thorac Oncol & Surg, Guangzhou, Peoples R China

[4] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan, Peoples R China

[5] Guangzhou Med Univ, Affiliated Hosp 1, China State Key Lab Resp Dis, Dept Pulm & Crit Care Med, Guangzhou, Peoples R China

[6] Southern Med Univ, Guangdong Prov Key Lab Trop Dis Res, State Key Lab Organ Failure Res, Dept Biostat,Sch Publ Hlth, Guangzhou, Peoples R China

[7] Wuhan Jin Yintan Hosp, Wuhan, Peoples R China

[8] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[9] Shenzhen Third Peoples Hosp, Shenzhen, Peoples R China

[10] Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Affiliated Hosp 2, Shenzhen, Peoples R China

[11] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China

[12] Guangzhou Med Univ, Guangzhou Eighth Peoples Hosp, Guangzhou, Peoples R China

[13] Cent Hosp Wuhan, Wuhan, Peoples R China

[14] Wuhan Hosp Tradit Chinese & Western Med, Wuhan Hosp 1, Wuhan, Peoples R China

[15] Chengdu Publ Hlth Clin Med Ctr, Chengdu, Peoples R China

[16] Hubei Polytech Univ, Affiliated Hosp, Huangshi Cent Hosp, Edong Healthcare Grp, Huangshi, Hubei, Peoples R China

[17] Wuhan Pulm Hosp, Wuhan, Peoples R China

[18] Wuhan Univ Sci & Technol, Tianyou Hosp, Wuhan, Peoples R China

[19] First Hosp Changsha, Changsha, Peoples R China

[20] Third Peoples Hosp Hainan Prov, Sanya, Peoples R China

[21] Huanggang Cent Hosp, Huanggang, Peoples R China

[22] Wenling First Peoples Hosp, Wenling, Peoples R China

[23] Third Peoples Hosp Yichang, Yichang, Peoples R China

[24] Hubei Univ Med, Affiliated Taihe Hosp, Shiyan, Peoples R China

[25] Xiantao First Peoples Hosp, Xiantao, Peoples R China

[26] Peoples Hosp Huangpi Dist, Wuhan, Peoples R China

来源：

EUROPEAN RESPIRATORY JOURNAL | 2020年 / 55卷 / 05期

关键词：

RESPIRATORY SYNDROME CORONAVIRUS; DIABETES-MELLITUS; MERS-COV; HYPERTENSION; INFECTION; OUTCOMES; DEATH; RISK; SARS;

D O I：

10.1183/13993003.00547-2020

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. Objective: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. Methods: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. Results: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424-5.048)), diabetes (1.59 (1.032.45)), hypertension (1.58 (1.07-2.32)) and malignancy (3.50 (1.60-7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16-2.77) among patients with at least one comorbidity and 2.59 (1.61 4.17) among patients with two or more comorbidities. Conclusion: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.

引用

页数：14

共 50 条

[1] Impact of comorbidity on patients with COVID-19 in India: A nationwide analysis
Singh, Priya
Bhaskar, Yogendra
Verma, Pulkit
Rana, Shweta
Goel, Prabudh
Kumar, Sujeet
Gouda, Krushna Chandra
Singh, Harpreet
[J]. FRONTIERS IN PUBLIC HEALTH, 2023, 10
[2] Comorbidity and its Impact on Patients with COVID-19
Adekunle Sanyaolu
Chuku Okorie
Aleksandra Marinkovic
Risha Patidar
Kokab Younis
Priyank Desai
Zaheeda Hosein
Inderbir Padda
Jasmine Mangat
Mohsin Altaf
[J]. SN Comprehensive Clinical Medicine, 2020, 2 (8) : 1069 - 1076
[3] Cardiovascular comorbidity and its impact on patients with COVID-19
Guan, Wei-jie
Liang, Wen-hua
He, Jian-xing
Zhong, Nan-shan
[J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
[4] Impact of COVID-19 in patients hospitalized with stress cardiomyopathy: A nationwide analysis
Hajra, Adrija
Malik, Aaqib
Bandyopadhyay, Dhrubajyoti
Goel, Akshay
Isath, Ameesh
Gupta, Rahul
Krishnan, Suraj
Rai, Devesh
Krittanawong, Chayakrit
Virani, Salim S.
Fonarow, Gregg C.
Lavie, Carl J.
[J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2023, 76 : 25 - 30
[5] Impact of COVID-19 on surgical emergencies: nationwide analysis
Lazzati, A.
Rousseau, M. Raphael
Bartier, S.
Dabi, Y.
Challine, A.
Haddad, B.
Herta, N.
Souied, E.
Ortala, M.
Epaud, S.
Masson, M.
Salaun-Penquer, N.
Coste, A.
Jung, C.
[J]. BJS OPEN, 2021, 5 (03):
[6] IMPACT OF BARIATRIC SURGERY ON OUTCOMES OF HOSPITALIZED PATIENTS WITH COVID-19: A NATIONWIDE ANALYSIS
Haseeb, Muhammad
Waqar, Maham
Faheela, Fnu
Hayat, Umar
Jirapinyo, Pichamol
Thompson, Christopher C.
[J]. GASTROENTEROLOGY, 2023, 164 (06) : S1458 - S1459
[7] Impact of COVID-19 on the incidence and outcomes of patients hospitalized with acute myocarditis: A nationwide analysis
Bansal, Agam
Faisaluddin, Mohammed
Agarwal, Siddharth
Patel, Harsh
Cremer, Paul
Menon, Venu
Jaber, Wael A.
[J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 71 : 247 - 248
[8] Prevalence and impact of diabetes in patients with COVID-19 in China
Du, Min
Lin, Yu-Xin
Yan, Wen-Xin
Tao, Li-Yuan
Liu, Min
Liu, Jue
[J]. WORLD JOURNAL OF DIABETES, 2020, 11 (10) : 468 - 480
[9] Nationwide Analysis of the Outcomes and Mortality of Hospitalized COVID-19 Patients
Isath, Ameesh
Malik, Aaqib H.
Goel, Akshay
Gupta, Rahul
Shrivastav, Rishi
Bandyopadhyay, Dhrubajyoti
[J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (02)
[10] A Nationwide Analysis of Ischemic Stroke Outcomes in Patients with COVID-19
Garg, Aayushi
[J]. NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →